Action INO INOVIO PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Inovio Pharmaceuticals, Inc.

Actions

INO

US45773H4092

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 17/07/2024 		Varia. 5j. Varia. 1 janv.
11,09 USD -0,36 % Graphique intraday de Inovio Pharmaceuticals, Inc. +19,50 % +81,21 %
11/07 INOVIO annonce qu'INO-3107 a reçu la désignation de passeport pour l'innovation dans le cadre du programme gouvernemental britannique Innovative Licensing and Access Pathway (ILAP) CI
02/07 Inovio Pharmaceuticals nomme Steven Egge directeur commercial MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
INOVIO - INO-3107 awarded the Innovation Passport Designation under U.K. Government's Innovative Licensing and Access Pathway
AQ
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
PR
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
PR
INOVIO Added to Russell 2000 Index Effective July 1, 2024
AQ
INOVIO Reports Inducement Grant Under Inducement Plan
PR
Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025
AQ
INOVIO Added to Russell 2000® Index Effective July 1, 2024
PR
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
PR
INOVIO Reports Inducement Grants Under Inducement Plan
PR
Inovio: Q1 Earnings Snapshot
AQ
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR
INOVIO Reports Inducement Grants Under Inducement Plan
PR
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
PR
INOVIO to Participate in Upcoming Investor Conferences in May
PR
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PR
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PR
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
AQ
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
PR
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
INOVIO Reports Inducement Grant Under Inducement Plan
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action INO
  4. Actualités Inovio Pharmaceuticals, Inc.
  5. Communiqués